entrevestor.com, written by Peter Moreira Kevin Sullivan had the pride of a guy showing off his new Cadillac. But it wasn’t a car he was displaying, it was the new laboratory that his company had recently moved into. The company is Halifax-based drug discovery outfit Appili Therapeutics Inc., which in May announced $3.3 million in funding, comprising equity, debt and grants. On the same day, Sullivan unveiled the company’s new lab in the Innovacorp Enterprise Centre in Halifax and introduced the team of PhDs working for the company. A month earlier, Appli had announced it received a special fast-track approval designation from the Food and Drug Administration. Not bad for a company that began last year. “Appili is a company that hasn’t been around long, and coming from where they started to where they are today is truly impressive,” said Scott Moffitt, the Managing Director of BioNova, the life sciences industry association in Nova Scotia. Appili is a notable company because of its leadership, its strategy and the story of how the company came together. Sullivan is a businessman operating in a segment that is often known for the high concentration of academics. He’s raised more than $40 million for various companies, and he brings a deep expertise in developing new drugs. Sullivan came to Nova Scotia in 2013 to take the helm at DeNovaMed, a Halifax company working on a cure for antibiotic-resistant viruses. He had previously spent 10 years (including four as COO) with London-based Viron Therapeutics Inc., which was developing a cardiovascular drug. Viron raised more than $35 million in equity and non-dilutive capital and took its lead product through Phase 2 trials. During his work in the biotech field, Sullivan met up with Brian Bloom and Jolyon Burton, the principals of the Toronto-based healthcare-focused investment boutique Bloom Burton & Co. Together, they decided to form a company in Halifax headed by Sullivan that would develop drug candidates. The first is ATI-1501, which aims to remove the nasty taste from an existing drug that treats Clostridium difficile infection, or CDI, an urgent antibiotic-resistant bacterial threat that causes 29,000 deaths annually. A drug called Metronidazole has been used to treat the condition since the 1970s, but kids with CDI don’t want to take it because of its dreadful taste. ATI-1501 removes the bitter taste. The Food and Drug Administration recently granted orphan drug designation to ATI-1501, meaning Appili could have an accelerated regulatory path and protection against competition for seven years. The company expects to begin clinical trials next year and have a product on the market in three or four years. The second drug candidate is ATI-1503, a drug that could fight deadly infections such as Klebsiella pneumoniae. The media is full of warnings about viruses that are resistant to antibiotics and Sullivan said this drug could help combat them, but it’s a longer, riskier project than the first drug. “We’re now entering a post antibiotic era, where a common cut could be deadly,” said Sullivan. “That’s what keeps us up at night.” Sullivan described Appili’s strategy as one based on “hitting home runs and singles.” The idea is that the drug for CDI can get to market quickly, but address a limited market. By selling the product, it could produce a steady income stream. That would help to finance the drug for antibiotic-resistant viruses, which could become a blockbuster drug. The strategy helped Sullivan attract $2.3 million in equity financing in the latest round — $1.8 million from individuals brought together by Bloom Burton, and $500,000 from Innovacorp. Appili supplemented the raise with funding from theAtlantic Canada Opportunities Agency and NRC Irap. “This is a seed round,” said Sullivan. “We’ll be looking to go back to the capital markets in the summer and close another round of financing in the fall.”]]>
BIONOVA CONTACT
#46 1344 Summer Street
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]
Recent Posts
- NEWS RELEASE: Doris Grant appointed Vice President Business Development and Strategy at BioNova
- MARS VR Lab
- Workinsights
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today
Business Wire National BioTech News
- RefleXion and Limbus AI Announce Technology Integration to Expedite Cancer Treatment Planning
- Devonian Health Group Reports Second Quarter 2024 Financial Results and Business Update
- Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
- dentalcorp to Participate at Upcoming Investor Conferences
- InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
- Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights
- Domain Therapeutics to Present Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology, at AACR 2024 Annual Meeting, Highlighting Clear Competitive Advantages of This Candidate
- Watchmaker Genomics Launches Watchmaker mRNA Library Prep Kits - Featuring a Rapid Workflow and Sensitive mRNA Detection
- STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests
- Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
RECENT NEWS
- NEWS RELEASE: Doris Grant appointed Vice President Business Development and Strategy at BioNova February 9, 2023
- MARS VR Lab January 25, 2022
- Workinsights January 25, 2022
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021 November 8, 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today November 2, 2021
- NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 11th Annual BioInnovation Challenge August 24, 2021
RECENT TWEETS
Notice: Trying to get property 'full_text' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 206
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1033
Notice: Trying to get property 'id_str' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1033
Notice: Trying to get property 'favorite_count' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1064
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1104
Notice: Trying to get property 'name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1104
·
@
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1123
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1123
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1123
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1307
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1307
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1307
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 601
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 601
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 601
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 619
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 619
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 619
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 579
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 579
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 579